We describe a child with dyserythropoietic anemia; thrombocytosis; functional platelet defect and megakaryocyte dysplasia. We show that (i) this constellation of hematopoietic abnormalities was due to a germline mutation within the 5′UTR of GATA1; (ii) the mutation impaired a 5′UTR GATA1 splicing site, promoting production of the shortened GATA1s isoform lacking the Nterminus; (iii) expression of the GATA1 N-terminus is restricted to erythroblasts and megakaryocytes in normal marrow, consistent with the patient's abnormal erythropoiesis and megakaryopoiesis. Our findings provide insights into the clinically relevant in vivo function of the N-terminal domain of GATA1 in human hematopoiesis.
Introduction
Germline mutations within the X-linked transcription factor GATA1 occur in a spectrum of childhood blood disorders (reviewed in [1] ). Alternative splicing produces two GATA1 isoforms [2] : full-length GATA1 (flGATA1) and shortened GATA1 (GATA1s), which lacks the N-terminal domain.
Rare defects known as "GATA1s mutations" [3] reduce synthesis of full-length GATA1 while GATA1s is still produced. Acquired GATA1s mutations drive transient myeloproliferative disorder and AML in Down syndrome patients (reviewed in [4] [5] [6] ). Germline GATA1s mutations in individuals without trisomy 21 have been associated with Diamond-Blackfan anemia (DBA) [7, 8] , a syndrome of RBC aplasia and otherwise normal hematopoiesis [9] . DBA-associated ribosomopathy impairs GATA1 synthesis [10] , perhaps because the complex structure of the GATA1 5′UTR demands error-free ribosomes for efficient translation. Thus, ribosomopathy has been mechanistically linked to GATA1 and erythropoiesis failure in DBA. However, thrombocytopenia with structural platelet abnormalities and dyserythropoiesis [11] as well as childhood myelodysplastic syndrome (MDS) [12] were reported in other GATA1s families. Since GATA1s patients are rare and clinically heterogeneous, the clinical impact of inherited GATA1s mutations on human hematopoiesis remains to be fully elucidated.
Results
We describe a child with dyserythropoietic anemia, megakaryocyte dysplasia and platelet malfunction due to a disease-causing mutation within the 5′UTR of GATA1. We explored the impact of this novel mutation on the expression of GATA1 splice variants in human bone marrow. Our findings support the role for the N-terminus of GATA1 in in vivo megakaryocyte function and erythropoiesis.
A 4-year old male developed fatigue and pallor secondary to anemia (hemoglobin: 4.4 g/dL). His growth and development were normal with no congenital malformations. His past blood counts revealed progressive macrocytic anemia with reticulocytopenia and persistent fetal hemoglobin first noted at 3 months of age, as well as chronic thrombocytosis (platelets: 387-947,000/mm 3 ) and occasional neutropenia with no frequent infections (lowest absolute neutrophil count:495/mm 3 ) ( Figure 1A ). The folate and vitamin B12 levels were normal. Normal DEB chromosome-breakage test and lymphocyte telomere length excluded Fanconi anemia and dyskeratosis congenita, respectively.
DBA was initially suspected due to progressive macrocytic anemia beginning in infancy [9] . However, the patient's bone marrow analysis revealed not only paucity of RBC precursors ( Figure 1B , which is not seen in classic DBA [9] . Accordingly, sequencing of the patient's nine DBA-associated ribosome genes (RPL11, RPL35a, RPL5, RPS10, RPS17, RPS19, RPS24, RPS26, and RPS7) and deletion-duplication analysis of RPS19, RPL5, RPL11, RPL35A, RPS17 and RPS26 produced normal results. Normal cytogenetics, MDS-FISH and blast count excluded MDS. Thus, we asked whether his anemia mimicking DBA [7, 8] but associated with megakaryocyte dysplasia [11] reflected a germline GATA1 defect. Indeed, Sanger sequencing revealed a novel mutation within the 5′UTR of GATA1 (c.-21A>G or c.-19-2A>G) at position 48,791,089 on the X-chromosome (GRCh38.p2 primary assembly), which affects the absolutely conserved A in the -2 position of the splice acceptor site ( Figure   1D ). Consistent with an X-linked recessive inheritance, mother was an asymptomatic carrier, and all healthy male siblings had wild-type GATA1 ( Figure 1D ).
We hypothesized the GATA1 c-.21A>G transcript splicing is abnormal as our in silico analysis [13] suggested disruption of a 5′UTR consensus splice site. Accordingly, the GATA1 c-.21A>G mutation decreased in vivo flGATA1 expression ( Figure 1E-F) , which is consistent with the GATA1s phenotype [7, 8, 11, 12] . The patient's anemia improved on corticosteroids similar to other GATA1s individuals [7, 8, 12] . Thus, the GATA1 c.-21A>G mutation produced the GATA1s phenotype through destruction of a splice site within the 5′UTR of GATA1 ( Figure 1G ).
Past clinical reports have generated conflicting in vivo data regarding the impact of inherited GATA1s mutations on megakaryopoiesis in non-Down syndrome patients [7, 8, 11] . However, accumulation of dysplastic megakaryocytes in the GATA1 c.-21A>G marrow with peripheral thrombocytosis strongly suggests that flGATA1 regulates human megakaryocyte proliferation and function in vivo in individuals without trisomy 21. Moreover, the GATA1 c.-21A>G platelets displayed subclinical aggregation deficiencies (Supplementary Figure 3) , further implicating flGATA1 in physiological megakaryopoiesis. Thus, we methodically examined GATA1 splicing in human marrow, hypothesizing that flGATA1 expression correlates with the role of flGATA1 in distinct lineages. To that end, we developed an immunohistochemistry assay specific for the GATA1 N-terminus (Figure 2A ). Full-length GATA1 was absent from the GATA1 c.-21A>G marrow, confirming that the mutation confers GATA1s phenotype ( Figure 2B-C) . Double-immunohistochemistry detected flGATA1 in healthy megakaryocytes and erythroblasts but not in other hematopoietic lineages ( Figure 2C) , consistent with the observation that loss of flGATA1 disrupted RBC and platelet production in our patient (Figure 1 ).
Discussion
GATA1 orchestrates the production of RBCs and platelets [14] [15] [16] . Alternative splicing provides an incompletely understood pathway to fine-tune this transcription factor's activity during hematopoiesis. Full-length GATA1 differs from the short isoform (GATA1s) by the presence of the 83 amino acid-long N-terminus, which activates GATA1-driven erythropoiesis [2, 17] and recruits flGATA1 to a subset of megakaryocyte and erythroblast genes [3] . Thus, GATA1 isoforms control partially overlapping but not identical transcriptional modules of erythroblast and megakaryocyte maturation. Acquired GATA1s mutations are key drivers of transient myeloproliferation and AML in Down syndrome [4] [5] [6] . Inherited GATA1s mutations that decrease production of flGATA1 through disrupting exon 2 splice sites [7, 8, 11] or the initiation codon [12] have been reported in rare non-Down syndrome patients (Figure 2 ). GATA1s patients uniformly develop hyporegenerative anemia, confirming that the N-terminus of GATA1 is indispensable for erythropoiesis. However, since the reported clinical symptoms in GATA1s individuals range from DBA [7, 8] to erythroblast and megakaryocyte dysplasia [11] and DBA progressing to MDS [12] , the role of flGATA1 in other hematopoietic cell lines needs clarification.
Striking accumulation of dysplastic megakaryocytes in the GATA1 c.-21A>G patient's marrow (Figure 1) suggests that loss of flGATA1 unleashes megakaryocyte proliferation in vivo, possibly due to de-repression of the E2F cell-cycle regulator [18] . In further support of this notion, independent ex vivo studies showed that hematopoiesis in GATA1s iPS cells is skewed towards generation of abnormal megakaryocytes at the cost of erythropoiesis [3] . Indeed, expression of the GATA1 N-terminus is restricted to erythroblasts and megakaryocytes (Figure 2) , supporting a physiological role of flGATA1 in these hematopoietic lineages. This assay may provide a future screening tool for GATA1s phenotype. Intriguingly, both thrombocytopenia [11] and thrombocytosis (this work) occur in GATA1s individuals, including GATA1s patients diagnosed with DBA [8] . A systematic evaluation of megakaryopoiesis in additional GATA1s patients will determine whether megakaryocyte dysplasia is universally seen in GATA1s individuals. Potential genotypephenotype correlations will remain unknown until more GATA1s patients are identified, especially since the same GATA1 c.220G>C mutation caused DBA-like phenotype in one family [8] and multilineage dysplasia in another [11] .
The GATA1 c.-21A>G platelets are defective (Supplementary Figure 3) . This is in agreement with ultrastructural platelet abnormalities described in GATA1 c.220G>C family [11] , likely secondary to disrupted cytoskeletal remodeling in flGATA1-deficient megakaryocytes [19] . Future studies will determine whether GATA1s patients develop clinically significant bleeding later in life.
Prominent megakaryocyte abnormalities (this work; [11] ) may provide subtle clinical clues to differentiate GATA1s mutations from "classical" DBA caused by ribosomopathy, which is defined as pure red blood cell aplasia [9] . GATA1 sequencing should be considered in males with congenital multi-lineage dysplasia and/or DBA-like clinical presentation. Interestingly, MDS-associated spliceosome mutations globally alter expression of multiple hematopoietic regulators, including GATA1 [20] . Given the potential risk of MDS in GATA1s patients [12] , hematopoiesis should be closely monitored in individuals with inborn GATA1s mutations.
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Cluster of differentiation
DEB Diepoxybutane
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